Avancées et synthèse des derniers congrès : ASCO-GU, EAU, AUA, ASCO concernant la prise en charge médicale des cancers urothéliaux

25 mars 2010

Auteurs : D. Amsellem-Ouazana, C. Theodore, J. Irani, S. Bernardini, J.-L. Bonnal, B. Chauvet, M. Colombel, J.-L. Davin, G. Laurent, T. Lebret, M. Maidenberg, C. Mazerolles, C. Pfister, M. Roupret, C. Roy, F. Rozet, F. Saint, M. Soulié, J. Guillotreau
Référence : Prog Urol, 2010, 20, S38, suppl. S1


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser


Faivre d’Arcier B., Celhay O., Pfister C., Soulié M., Roset F., Rouprêt M., et al. T1urothelial cell carcinoma: prognostic significance of lamina propria invasion microstaging (T1A/B) 24th annual EAU congress :  (2009). 
Caviezel A., Klein J., Iselin C.E. Prognostic value of the subclassification T1 in the micro-invasive bladder cancer on a medium term basis Eur Urol suppl 2009 ;  8 : 286abstract 664.
Olsson H.O.M., Jahnson S. Sub staging of T1 bladder tumours Eur Urol suppl 2009 ;  8 : 287abstract 665.
Raventos Busquets C.X., Orsola A., Cecchini, et al. Second-TUR of initial high grade T1 bladder cancer after-BCG and according to lamina propria invasion microstaging (T1 a/b) Eur Urol suppl 2009 ;  8 : 282abstract 646.
Finch W.J.G., Habib M.R., Banerjee G.K. Holmium laser ablation of recurrent superficial bladder tumours under topical anaesthesia using a flexible cystoscope in anticoagulated patients Eur Urol suppl 2009 ;  8 : 374abstract 1015.
Kakiashvili D., Van Rhijn B.W.G., Jewett M.A.S., et al. Long-term follow-up for primary T1 high-grade bladder cancer. Does BCG really prevent progression? Eur Urol suppl 2009 ;  8 : 282abstract 645.
Unda M., Madero R., Solsona E., et al. Long-term follow up of the effectiveness of standard dose BCG (81mg connaught strain) comparing with a three fold reduce dose (27mg) in high risk non muscle invasive bladder cancer. CUETO group Eur Urol suppl 2009 ;  8 : 284abstract 655.
Malmström P.U., Sylvester R., Crawford E.D., et al. Immunotherapy or chemotherapy as local therapy of urinary bladder cancer - which is the most effective? Report on a meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscle invasive bladder cancer Eur Urol suppl 2009 ;  8 : 283abstract 651.
Stenzl A.S., Roessler W.R., Fradet Y.F., et al. Hexvix® fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: a multicentre, prospective, randomized study Eur Urol suppl 2009 ;  8 : 373abstract 1010.
Mowatt G., N’Dow J., Shihua Z., et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy Eur Urol suppl 2009 ;  8 : 373abstract 1011.
Cottrell A., McPhail S., Ayres B., et al. Prognostic factors for upper tract transtitonal cell carcinoma and metachronous urothelial tumours: evaluating 888 patients from the BAUS Section of Oncology Urological Cancer Observatory Project Eur Urol suppl 2009 ;  8 : 150abstract 120.
O’Brien T.S. ODMIT C: a prospective randomised multicentre trial of a single post-operative dose of intravesical mitomycin C to prevent bladder cancer formation following nephroureterectomy for upper tract TCC (UTTCC) Eur Urol suppl 2009 ;  8 : 373abstract 1013.
Stadler W.M., Lerner S.P., Groshen S., et al. Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organconfined node-negative urothelial bladder cancer J Clin Oncol 2009 ;  27 : abstr 5017.
Hahn N.M., Stadler W.M., Zon R.T., et al. A multicenter phase II study of cisplatin (C), gemcitabine (G), and bévacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475 J Clin Oncol 2009 ;  27 : abstract 152.
Huddart R.A., James N.D., Adab F., et al. BC2001: a multicenter phase III randomized trial of standard versus reduced volume radiotherapy for muscle invasive bladder cancer (ISCRTN: 68324339) J Clin Oncol 2009 ;  27 : abstract 948.

© 2010 
Elsevier Masson SAS. Tous droits réservés.